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Catharina GM Groothuis-Oudshoorn1*, Jilles M Fermont1,2, Janine A van Til1 and Maarten J IJzerman1Abstract
Background: Emerging developments in nanomedicine allow the development of genome-based technologies for
non-invasive and individualised screening for diseases such as colorectal cancer. The main objective of this study
was to measure user preferences for colorectal cancer screening using a nanopill.
Methods: A discrete choice experiment was used to estimate the preferences for five competing diagnostic
techniques including the nanopill and iFOBT. Alternative screening scenarios were described using five attributes
namely: preparation involved, sensitivity, specificity, complication rate and testing frequency. Fourteen random and
two fixed choice tasks, each consisting of three alternatives, were offered to 2225 individuals. Data were analysed
using the McFadden conditional logit model.
Results: Thirteen hundred and fifty-six respondents completed the questionnaire. The most important attributes
(and preferred levels) were the screening technique (nanopill), sensitivity (100%) and preparation (no preparation).
Stated screening uptake for the nanopill was 79%, compared to 76% for iFOBT. In the case of screening with the
nanopill, the percentage of people preferring not to be screened would be reduced from 19.2% (iFOBT) to 16.7%.
Conclusions: Although the expected benefits of nanotechnology based colorectal cancer screening are improved
screening uptake, assuming more accurate test results and less preparation involved, the relative preference of the
nanopill is only slightly higher than the iFOBT. Estimating user preferences during the development of diagnostic
technologies could be used to identify relative performance, including perceived benefits and harms compared to
competitors allowing for significant changes to be made throughout the process of development.
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assessmentBackground
Approximately 436,000 people in Europe are newly diag-
nosed with colorectal cancer (CRC) annually [1]. World-
wide this figure reaches more than one million and these
numbers are expected to increase with an ageing popu-
lation [2]. In most European countries the 5-year sur-
vival rate is less than 60% [3]. If CRC is diagnosed at an
early stage, the 5-year survival rate increases to almost
90% [4]. Screening is carried out, dependent on local
guidelines, using immunochemical faecal occult blood test
(iFOBT), colonoscopy, sigmoidoscopy, virtual colonoscopy
or double contrast barium enema [5]. Population-based* Correspondence: c.g.m.oudshoorn@utwente.nl
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distribution, and reproduction in any mediumscreening, using one of these methods, is recommended in
most countries. The requirements for a test to be used as a
screening instrument include high sensitivity, low cost and
low burden to the participant.
Improved technology combined with increased know-
ledge and understanding of DNA sequencing has led to
a better understanding of the aetiology of common dis-
eases such as CRC and the potential use of biomarkers
in disease detection. Several studies reporting the use of
biomarkers in blood samples and gastro-intestinal fluid
have been published [6-8]. For instance, the nanopill is a
foresight of a digestible pill with diagnostic capabilities
on molecular level [9]. The nanopill may be an alterna-
tive to current CRC screening modalities such as the
iFOBT and sigmoidoscopy, with the promise of improved
test performance and decreased burden of screening toioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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screening modalities and the nanopill is that the latter
does not look for a tumour but rather it screens the par-
ticipant’s gastro-intestinal fluid for hypermethylated
DNA as a cancer marker. If the technology is being de-
veloped, it is suggested that the nanopill could be taken
at home with minimal preparation.
Since the nanopill is still in development, the actual
benefits in terms of increased test performance and
health impact are unknown. In medical product develop-
ment, decisions with regard to future development have
to be made during the product development cycle.
These decisions may benefit from early assessment of
the potential of the product to compete in the healthcare
market. Health Technology Assessment (HTA) is mostly
carried out when a technology is fully developed and lit-
tle to no adjustments can be made, possibly resulting in
bad investments and product failure [10]. In contrast, an
early assessment allows for timely decision-making so
that significant product changes can still be made
throughout the process of development [11].
In the case of the nanopill, it is important to under-
stand the added value compared to its competitors and
predictors for screening uptake in order to determine
priorities in product development and targeting. Uptake
rates for population-based CRC screening programs
range between approximately 20% (Czech Republic) [12]
and 70% (Finland) [13] for FOBT. Despite its favourable
effect, the uptake for CRC screening remains generally
poor, which has been variably accounted for by patient-
related barriers [14-17], physician factors [18,19] and
system failure [20,21]. As the population benefit and
acceptance of screening programs largely depend on par-
ticipation rates, the public perception of screening bene-
fits and harms are important to estimate the potential of
the technology in this intended target area. Current screen-
ing programs for CRC could be improved with regard to
accuracy, burden, risks and required preparation [22-24].
The first objective of the study was to estimate public
preferences for test characteristics (attributes) of screen-
ing technology and their relative importance in judging
the overall attractiveness of a screening test. The second
objective of the study was to estimate the predicted
uptake of screening with the nanopill compared to its
competitors while taking into account the attributes of
the test.
Methods
Study population
The study was conducted among the general popula-
tion in the Netherlands (NL) and the United Kingdom
(UK). In contrast to the NL, a population-based CRC
screening programme has already been implemented
in the UK.The sample was selected from an international Internet
panel maintained by Survey Sampling International (SSI)
in May 2011. SSI randomly recruited and invited 2225 re-
spondents from the NL and the UK by email. Inclusion
criteria were based on the advice for CRC screening given
by the council of the European Union (EU) [25]. Both
men and women aged between 50 and 74 years with ab-
sence of CRC were eligible. To prevent duplicates, SSI
used respondent verification. For all questionnaires unique
one-click links were created allowing respondents to dir-
ectly access the survey. Respondents were able to save
their progress at any time and complete the questionnaire
within one month after invitation. According to the NHS
Health Research Authority information, this type of study
did not require approval from an ethics committee in the
UK. The internet survey data was collected following ESO-
MAR codes and guidelines.
Sample size
For this type of study it is recommended to have a mini-
mum sample size of 300 [26]. We aimed for at least 800
respondents per country in total to increase the power
of the study and to anticipate on an expected large
non-response. In total 2225 respondents were invited
to participate, 1100 (49%) in the UK and 1125 (51%) in
the NL.
Study measures
The questionnaire consisted of two parts. In the first part
preferences of respondents with regard to different CRC
screening modalities were elicited with a discrete choice
experiment (DCE). In the second part socio demographics
and other characteristics were asked: gender, age, marital
status, employment status, educational level, family his-
tory of CRC, screening experience, current health status,
and perceived individual risk of CRC. The expected time
of questionnaire completion was approximately twenty
minutes.
DCE construction
The current study employs an approach called DCE or
conjoint analysis to elicit the general public’s preferences
for screening programs. The DCE is based on random
utility theory and is consistent with Lancaster’s eco-
nomic theory of value [27,28]. Random utility theory al-
lows the researcher to elicit preferences for complex
multidimensional goods or services, from which models
of (relative) preferences for different attributes of a good
or service can be estimated [29,30].
In this study, respondents were presented with mul-
tiple three-profile choice sets (triplets). Each choice set
consisted of a random combination of attribute levels
that spans the full range of actual to perfect performance
of the different diagnostic techniques for CRC. An example
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screening tests can be found in the Additional file 1 and
Additional file 2.
The design of the DCE was based on good research
practices for conjoint analysis [31]. The choice for the at-
tributes and levels for the DCE were based on previous
preference studies on CRC screening [32-37]. Attributes
of the diagnostic tests reported in the literature that were
considered important in assessing test performance ac-
cording to clinicians, researchers, policy- and decision-
makers were included. The six attributes with associated
levels included in this study were: preparation (no prep-
aration, laxatives, enemas, diet plus laxatives), tech-
nique (stool, short tube, long tube with sedation, pill),
sensitivity (70%, 80%, 90%, 100%), specificity (70%,
80%, 90%, 100%), complication rate (none, 1/10.000,
10/10.000, 100/10.000), and the required frequency of
testing (annual, biennial, every 5 years, every 10 years).
It was decided to replace the attribute “process” as
used in many other studies by “technique”, as this
would better indicate the technology. The process char-
acteristics of each test were given in the study informa-
tion sheet. Another important attribute found in the
literature is discomfort. However, since attribute inde-
pendence is important discomfort was not included as
it was also captured by the attributes “process” and
“preparation”. Except for frequency, all attributes are
product related characteristics. Testing frequency is an
important factor for feasibility and cost-effectiveness of
screening. Levels for frequency were related to frequen-
cies found in existing CRC screening programs within
the EU. Costs were not included as an attribute because
in the UK there are no out-of-pocket costs for the
CRC population-based screening programme and if a
population-based screening would be introduced in the
Netherlands, like other current screening programs, public
resources would be used to cover the financial cost.
Combining six attributes with four levels each resulted
in 4096 (46) different combinations that could be used
as different hypothetical screening profiles. There are
11.4 .109 possible combinations of three-alternative choice
sets. Sawtooth SSI Web System v.7.0 was used to generate
999 unique questionnaires, each with fourteen profile
pairs randomly drawn from a fractional factorial design
with a balanced overlap. Balanced overlap was used to add
some degree of level overlap, without duplicating scenar-
ios in choice tasks, to provide an opportunity for more
discrimination for when people use non-compensatory
rules and to improve the precision of estimates of inter-
action terms.
Respondents were asked to imagine themselves eligible
for CRC screening. In each question, respondents were
asked to state their preferred scenario for CRC screening
from a set of three hypothetical screening tests (Figure 1).After a decision was made, respondents were also of-
fered not to participate in screening and were asked to
choose between the previous chosen test and no screen-
ing. This type of dual-none response is called DR-2Max
because it is a choice between two alternatives: the pre-
ferred and “none” [38]. The dual-none response question
was included to prevent overestimation of screening up-
take by assuming that all respondents would actually use
the preferred test [39]. An example scenario and a
choice set with response instructions were included to
help respondents fill in the questionnaire.
Pilot testing
Prior to distributing the questionnaire a pilot was conducted
with thirty respondents. It was found that all respondents
could evaluate the sixteen full-profile choice tasks in a rea-
sonable amount of time but the phrasing of the attributes
sensitivity, specificity and preparation was adjusted slightly
to increase the understanding of the questions.
Statistical analysis
Characteristics of the two samples, i.e. socio demographics,
screening experience, perceived risk and family history of
CRC, and health status were described using percentages
for categorical variables and the mean (sd) for continuous
variables. Differences between the two samples (NL and
UK) were tested with Chi-square tests and t-tests.
Data of the DCE was analysed by stacking the dual re-
sponses for each respondent [38]. The response to the
first choice was set up as a forced choice task between
three scenarios and the second response was set up as a
choice task among four alternatives including “none”.
For respondents where the second choice was not
“none” the first choice set was redundant and removed
from the dataset. The stacked data was analysed using a
conditional logit model.
We estimated the following model for the latent utility
U for a CRC screening alternative:
U ¼ V þ ε ¼ β0 þ
X24
i¼1
βixi þ ε
V is an explainable, systematic term specified as a lin-
ear function of the CRC screening alternatives. xi has a
value of one if the associated level of a certain attribute
is present in the particular screening alternative, -1 if the
associated level is present and belongs to the reference
level of the attribute and zero otherwise. βi are the part-
worth utility parameters for all levels of the attributes. ε
is the random error, representing the individual variation
in preferences. The constant term β0 is an “alternative
specific constant”, indicating the relative weight on aver-
age placed by individuals on screening programmes
compared to no screening. It is assumed that each
Figure 1 Choice set example.
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mises her/his utility (U) amongst the three alternatives in
the choice set. Note that the utility (U) is not a cardinal
utility on a scale between 0 and 1. In fact one can only
interpret relative utility differences between scenarios.
Effects coding was used for the parameter estimation.
Parameter coefficients, corresponding 95% confidence
intervals and p-values are presented.
From the estimated utility scores, the expected uptake
of a screening alternative i was predicted as the prob-
ability of accepting this screening alternative with the
formula [40,41]:
P Accepting alternative test ið Þ ¼ 1
1þ e−V i :
The expected utility Vi of screening test i was calcu-
lated by adding the part-worth utilities for the different
attributes corresponding with the different levels. This
model assumes that an alternative with expected utility
V equals zero has a probability of acceptance of 50%.
Due to the effects coding, all parameters are estimated
relative to the grand mean, which has an expected utility
of zero. In other words: the mean indirect utility over all
possible screening options is fixed at zero. In addition,this means that the expected uptake rates are estimated
relative to the uptake rate of this grand mean.
Each competing screening alternative was represented
by the attribute levels that approximates most closely
with the actual values: iFOBT with no preparation, stool,
80% sensitivity, 90% specificity, no complication rate and
biennial testing; sigmoidoscopy: preparation with en-
emas, short tube, 70% sensitivity, 90% specificity, 10 per
10.000 complication rate and screening every 5 years;
colonoscopy: preparation with diet plus laxatives, long
tube with sedation, 90% sensitivity, 90% specificity, a
complication rate of 100 per 10.000 and a 10 year inter-
val; nanopill: preparation with laxatives, pill, 100% sensi-
tivity, 100% specificity, a complication rate of 1 per
10.000 and yearly testing. To estimate the minimal test
requirements for the nanopill to be of additional benefit,
trade-offs made by respondents were examined in a sen-
sitivity analysis by varying the levels of the attributes. Fi-
nally, the probability of choosing between screening with
test i or no screening was estimated with the multinomial
logit model [42].
To study the effect of personal characteristics on the
likelihood of choosing ‘no screening’, interactions be-
tween the alternative specific constant and the follow-
ing categorical variables were included in the previous
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(female vs male), age (in years), marital status (married
vs unmarried), employment status (full-time/part-time/
self-employed vs homemaker/unemployed/retired), educa-
tion (college/university vs less than college), family history
(yes vs no/not known), screening experience (yes vs no),
health status (excellent/(very) good vs fair/poor ), and risk
perception (yes vs no). Effects of personal character-
istics on preferences for attributes of the tests were not
examined.
The fit of the models was assessed with McFadden’s
pseudo R-squared and compared to each other with like-
lihood ratio chi-square statistics. Analyses were done in
Stata v.11.0 with a significance level of p < 0.05.
Results
Study population
There were 1649 respondents in total from which 292
were excluded; 31 respondents due to the presence of
CRC and 262 respondents did not fully complete the
survey. This results in a response rate of 61% (1356 out
of 2225). A response rate of 69% was achieved in the UK
and 53% in the NL. The characteristics of the respondents
are presented in Table 1. In total 11% (147 out of 1356)
had a family history of CRC, 32% (438 out of 1356) had ex-
perience with CRC screening, and 23% (317 out of 1356)
perceived themselves at risk for developing CRC.
In both countries the majority of respondents were re-
tired, but the current employment status differed be-
tween the countries (χ2 = 47.7, 5df, p < 0.001). The mean
age of the study sample was 60.5 (sd = 5.9). The re-
spondent sample from the UK had a higher response
rate (χ2 = 39.4, 1df, p < 0.001), were higher educated
(χ2 = 78.6, 3df, p < 0.001) and had more screening experi-
ence (χ2 = 84.6, 1df, p < 0.001) compared to the Dutch
sample. Respondents from the NL had a higher per-
centage of respondents with a positive family history of
CRC (χ2 = 13.2, 2df, p = 0.001).
DCE results
The estimated β-coefficients for the attribute levels are or-
dered as expected and statistically significant at the alpha
<0.001 level, except for laxatives (p = 0.02), annual screening
(p = 0.104) and screening every five years (p = 0.74), see
Table 2. From the estimated part-worth utilities it can be
concluded that respondents prefer a non-invasive test that
is highly sensitive, requires no preparation, offered biennial,
highly specific and has no complications. The least pre-
ferred screening combination is an invasive test that re-
quires much preparation, has low sensitivity and specificity,
a high screening interval and a high complication rate.
The difference between the part-worth utilities for the
levels indicates the utility that could be gained by chan-
ging (attaining) this level. As such, it can be concluded thatthe nanopill has the highest perceived utility. However, the
utility to be gained from changing from iFOBT to nanopill
screening is smaller than if an improvement from 90% to
100% sensitivity could be attained (0.28). When taking into
account that iFOBT is currently seen as the screening test
of choice, the highest improvement in utility by changing a
single attribute of the test could be obtained by omitting
the need for preparation (0.42).
The nanopill has the highest overall expected utility
(1.31) compared to the other screening alternatives. The
difference in utility between the nanopill and the iFOBT
is 0.17, which is statistically significant (p = 0.006). The
estimated utility for sigmoidoscopy (-0.51) and colonos-
copy (-0.44) is smaller than for no screening (-0.29),
meaning that no screening is preferred (on average) to
sigmoidoscopy and colonoscopy.
The absolute difference in the parameter estimates be-
tween attribute levels is the largest for technique, namely
0.85, which indicates that this is the most important at-
tribute in the choice for screening tests. It is two to
three times as large as the differences for specificity
(0.31), complication rate (0.27) and frequency (0.38)
and also larger than for preparation (0.57) and sensitiv-
ity (0.66). This implies that attributes related to the
screening method (technique and preparation) appear
to be more important than attributes related to the
process of screening (complications and frequency).
In Figure 2 the relative attribute importance and rela-
tive preference of levels of each attribute are given in
order of the attribute importance such that 0 corre-
sponds to the least desirable attribute level (long tube
with sedation) and 1 with the most desirable attribute
level (pill). Higher values indicate that the attribute level
is preferred to levels with lower values. The wider the
range, the more critical the attribute is in the decision
making process of screening participation.
Interaction model for no screening
A total of 93 (6.9%) of the respondents consequently
chose not to be tested. In contrast, 908 (67.0%) of the re-
spondents consistently selected screening. This indicates
that for the majority of respondents, the decision to par-
ticipate in CRC screening is made independent of the
actual test, its performance or the perceived burden of
testing involved. Family history (p = 0.024), screening
experience (p < 0.001) and risk perception (p < 0.001)
significantly interact with no screening (Table 3). In
other words, the utility of screening is higher where
there is a family history of CRC, screening experience
and higher perceived risk of developing CRC them-
selves and thus respondents with these characteristics
are more likely to choose in participate to screening.
For the remaining 355 (26.2%) respondents, the prefer-
ence for no screening over the preferred screening
Table 1 Self-reported characteristics of respondents (n = 1356)
Characteristics Total (%) United Kingdom (%) The Netherlands (%)
Response/invited 1649/2225 (74) 870/1100 (79) 779/1125 (69)
Completed questionnaires 1356 (61) 763 (69) 593 (53) p < 0.001
Gender p = 0.842
Male 691 (51) 387 (51) 304 (51)
Female 665 (49) 376 (49) 289 (49)
Age (years) 60.5 (5.9) 60.7 (6.1) 60.2 (5.8) p = 0.127
Marital status p = 0.923
Married 896 (66) 505 (66) 391 (66)
Not married 460 (34) 258 (34) 202 (34)
Current employment status p < 0.001
Full-time 248 (18) 137 (18) 111 (19)
Part-time 167 (12) 82 (11) 85 (14)
Self-employed 88 (7) 61 (8) 27 (5)
Homemaker 150 (11) 51 (7) 99 (17)
Unemployed 122 (9) 73 (10) 49 (8)
Retired 581 (43) 359 (47) 222 (37)
Education p < 0.001
Public/primary school 96 (7) 63 (8) 33 (6)
High school 605 (45) 260 (34) 345 (58)
Trade/technical qualification 205 (15) 136 (18) 69 (12)
College/university 450 (33) 304 (40) 146 (25)
Family history CRC p < 0.001
Yes 147 (11) 63 (8) 84 (14)
No 1123 (83) 655 (86) 468 (79)
Do not know 86 (6) 45 (6) 41 (7)
Experience with screening p < 0.001
Yes 438 (32) 325 (43) 113 (19)
No 918 (68) 438 (57) 480 (81)
Health status p < 0.001
Excellent 105 (8) 49 (6) 56 (9)
Very good 328 (24) 218 (29) 110 (19)
Good 498 (37) 254 (33) 244 (41)
Fair 333 (25) 181 (24) 152 (26)
Poor 92 (7) 61 (8) 31 (5)
Perceived risk developing CRC p = 0.663
Yes 317 (23) 175 (23) 142 (24)
No 1039 (77) 588 (77) 451 (76)
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tasks. In a subgroup analysis for this group, the attri-
butes technique and preparation are by far the most im-
portant, and the effect of sensitivity is much smaller
compared to the group as a whole. In 14.3% of all 21694
choice tasks no screening was preferred to one of thethree screening alternatives. The estimated part-worth
utilities estimates of the attribute levels are almost the
same as in the model without the interaction terms.
McFadden’s pseudo R for the interaction model equals
12.6% and the interaction model significantly improves
the model fit (χ2 = 1038.5, p < 0.001).
Pi
ll
St
oo
l
Lo
ng
 tu
be
Sh
or
t t
ub
e
10
0% 90
%
80
%
70
%
N
o 
pr
ep
ar
at
io
n
La
xa
tiv
es
En
em
as
D
ie
t p
lu
s 
la
xa
tiv
es
Bi
en
ni
al
Ev
er
y 
5 
ye
ar
s
An
nu
al
Ev
er
y 
10
 y
ea
rs
10
0% 90
%
80
%
70
%
N
on
e
1/
10
.0
00
10
/1
0.
00
0
10
0/
10
.0
00
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Technique Sensitivity Preparation Frequency Specificity Complications
Figure 2 Relative importance of colorectal cancer screening
attributes and attribute levels.
Table 2 Respondents preferences for colorectal cancer
screening
Attribute level β − coefficient 95% CI
Preparation
No preparation 0.38 (0.02)a 0.34 to 0.42
Laxatives −0.03 (0.01)b −0.06 to -0.01
Enemas −0.16 (0.01)a −0.19 to -0.13
Diet plus laxatives# −0.19 (0.02)a −0.22 to -0.16
Technique
Pill 0.48 (0.02)a 0.44 to 0.52
Stool 0.24 (0.02)a 0.20 to 0.28
Long tube with sedation# −0.34 (0.02)a −0.39 to -0.30
Short tube −0.37 (0.02)a −0.41 to -0.33
Sensitivity
100% 0.36 (0.02)a 0.32 to 0.39
90% 0.08 (0.01)a 0.05 to 0.10
80% −0.14 (0.01)a −0.17 to -0.11
70%# −0.30 (0.02)a −0.33 to -0.26
Specificity
100% 0.15 (0.01)a 0.12 to 0.17
90% 0.06 (0.01)a 0.03 to 0.09
80% −0.04 (0.01)a −0.07 to -0.02
70%# −0.16 (0.02)a −0.19 to -0.13
Complications
None 0.14 (0.02)a 0.11 to 0.17
1/10.000 0.04 (0.01)a 0.01 to 0.06
10/10.000 −0.04 (0.01)a −0.07 to 0.02
100/10.000# −0.13 (0.02)a −0.16 to -0.10
Frequency
Biennial 0.17 (0.02)a 0.14 to 0.21
Annual# 0.03 (0.02) −0.01 to 0.07
Every 5 years 0.01 (0.02) −0.03 to 0.04
Every 10 years −0.21 (0.02)a −0.26 to -0.17
No screening −0.29 (0.03)a −0.36 to -0.23
#: reference level in effects coding; ap-value < 0.005; bp-value < 0.05; 65079
Observations, 1356 respondents. McFadden R2 = 11.0%.
Table 3 Predictors for screening participation
Patient characteristic β − coefficient (se)
Interaction model
No screening 0.05 (0.10)
Interaction terms with no screening
Netherlands −0.13 (0.07)
Male −0.08 (0.07)
Perceived risk −0.56 (0.10)a
Health status high/excellent −0.02 (0.07)
Screening experience −0.50 (0.09)a
Age 0.007 (0.007)
Family history −0.29 (0.13)a
Education high −0.06 (0.07)
Married −0.06 (0.07)
Employed −0.04 (0.08)
Likelihood ratio χ2 8414a
McFadden R2 12.6%
ap-value < 0.005.
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The expected average uptake of CRC screening was 57.3 %
(CI 55.7% to 58.8%). The uptake for the annual screening
with the nanopill would be 78.8% (CI 77.0% to 80.5%),
which is 3 percentage points higher than for the iFOBT.
Colonoscopy and sigmoidoscopy are the least favourable
screening alternatives (Table 4).
The test characteristics of the nanopill were hypo-
thetical. Changing the frequency of taking the nanopill
from annually to biennial would increase the expected
uptake by 2.2 percentage points. The nanopill shouldhave at least 90% sensitivity, 95% specificity and be
used at a frequency of every two years to be equally
attractive as biennial iFOBT testing. Assuming that
CRC screening uses iFOBT, 19.2% of the respondents
would choose not be screened. In case of screening
with the nanopill, 16.7% of the respondents would
prefer not to be screened.
Table 4 Predicted choice probabilities for the different screening alternatives with varying scenarios for the nanopill
Screening alternative Sensitivity Specificity Complication rate Frequency Predicted probability (95% CI)
No screening - - - - 42.7% (41.2% to 44.3%)
Colonoscopya 90% 90% 100/10000 10 years 39.2% (36.8% to 41.6%)
Sigmoidoscopyb 70% 90% 10/10000 5 years 37.5% (35.2% to 39.8%)
iFOBTc 80% 90% None 2 years 75.8% (73.9% to 77.7%)
1: Nanopilld 100% 100% 1/10000 Annual 78.8% (77.0% to 80.5%)
2: Nanopilld 100% 100% 1/10000 2 years 81.0% (79.4% to 82.6%)
3: Nanopilld 100% 90% 1/10000 Annual 77.3% (75.4% to 79.2%)
4: Nanopilld 90% 100% 1/10000 Annual 73.8% (71.7% to 75.7%)
5: Nanopilld 95% 95% 1/10000 Annual 75.6% (73.7% to 77.4%)
6: Nanopilld 90% 95% 1/10000 2 years 75.6% (73.7% to 77.4%)
aDiet plus laxatives, long tube with sedation; bEnemas, short tube; cNo preparation, stool; dLaxatives, pill.
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In this study public preferences for the screening of
CRC were elicited to understand the potential of new
biomarker based screening approaches. The results of
the study indicate that the attribute “technique” was most
important followed by the “sensitivity” of the test. When
assuming that the nanopill will outperform the iFOBT on
sensitivity and specificity, the predicted uptake to screen-
ing with the nanopill is three percentage points higher
than with the iFOBT.
Previous studies have found that the sensitivity of a
test is the most important characteristic of a screening
test in CRC [35,43]. The finding that sensitivity was not
the most important criterion in this study might be
explained by the framing of the levels i.e. the use of a
“perfect” sensitivity level of 100% and/or the smaller con-
trast between the different levels for sensitivity (70% to
100% instead of 40% to 90% in other studies). Attribute
importance is a function of the range of attribute levels
and wider ranges almost certainly will result in higher
relative importances [30,44]. Moreover, it is unclear
whether the respondents actually understood the actual
numerical rates that were presented instead of thinking
of them as categories like ‘very low’, ‘low’, ‘moderate’ and
‘high’. Alternatively, the graphical presentation of sensi-
tivity levels might have influenced interpretation [43].
Conversely, the high importance given to the technique
might be related to the extensive qualitative informa-
tion given about different screening techniques prior
to the DCE questions than the other attributes. In
addition, the attention of the nanopill as a novel tech-
nique for diagnosis might have resulted in higher utility
of this level.
Previous studies using stated preference techniques
such as DCE in early stage consumer research and new
product development have resulted in a better under-
standing of consumer needs [45], quality improvement
of products and services [46], reduced time to market,prevented wasting resources on producing and evaluat-
ing inappropriate prototypes [47], estimated preferences
for services or technologies that are not yet available and
optimized screening uptake [43].
The results of this study give insight in the trade-offs
made by the public in valuing screening techniques and
the effect of the screening technique on predicted up-
take. The results of this study may support development
decisions for the nanopill.
The results of this study confirmed to the developers
of the nanopill that it is important to focus on sensitivity
and preparation, as these are the most important attri-
butes of screening, in order to meet the priorities of its
future users and thereby increase the product success.
However, the room for improvement is limited, it seems
that the public is not as averse to the handling of stool
samples as the developers believed, indicated by the
small actual difference in utility between stool sample
and no preparation.
Also, the currently proposed screening technique of
the iFOBT performs reasonably well with regard to sen-
sitivity while the costs are rather low. Although the costs
of the pill are currently unknown, it is unlikely that such
a technologically advanced method will become cheaper
than the low tech iFOBT screening. The nanopill outper-
formed other diagnostic tests in part due to its promise
of higher sensitivity. However, in the early stage of devel-
opment of the device, it is unknown whether this prom-
ise can be realised. Moreover, sensitivity over time is
more important for screening than single test sensitivity
[24,48] and the sensitivity of iFOBT could be improved
if this relatively cheap test is taken more frequent [49].
The results of this study indicate that frequency of test-
ing is a less important decision characteristic for the
population.
The results of this study have to be interpreted with
caution. First, the issue of respondent consistency should
be considered. In this study, two fixed choice tasks
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sistency (test–retest). It was decided not to exclude res-
pondents who failed this test because these seemingly
‘irrational’ responses might actually be ‘rational’. Delet-
ing them may induce sample selection bias and lead to a
reduction in model efficiency [50]. To examine the ef-
fects of respondent’s consistency, a second analysis was
performed including only respondents who passed the
consistency test. The relative order of the three most im-
portant attributes (technique, sensitivity and preparation)
did not change.
A second limitation of our study is the interpretation
of stated preference techniques and its relationship with
actual uptake of screening. The predicted uptake to
screening in the study is high compared to actual uptake
rates in CRC. The highest actual screening uptake docu-
mented was 71% (Finland) [13], which is lower than the
predicted uptake to screening for iFOBt in this study. A
comparable predicted uptake rate of 72% was found for
biennial iFOBT screening in the Netherlands by van
Dam [34]. The results of this study indicate that the de-
cision to participate in screening is, for a large part,
independent of the test characteristics itself. It may be
more likely that this decision depends on the character-
istics and circumstances of each individual.
Finally, it is known that the outcomes from a DCE in
terms of part-worth utility and relative importance esti-
mates depend on the choice of the attribute levels [44].
It is only when the attribute levels are a reflection of the
true range of alternatives that the outcomes are reliable
estimates of actual preferences. However, in the specific
case of the nanopill, the actual performance of the novel
technology is yet unknown and has to be determined
[43]. The same holds true for the choice of comparators.
We selected four comparators based on their frequency
of use in the diagnosis of CRC. Other comparators such
as virtual colonoscopy and video capsule endoscopy
were not included in the study because they are not of-
fered as standard screening tools within the EU.
Conclusions
Despite the expected benefits of a nanopill based screen-
ing programme in terms of improved screening uptake,
earlier diagnosis and more accurate test results, the prefer-
ence for the nanopill compared to its competitors is only
slightly higher. Although these findings agree with previ-
ous studies and suggest that the nanopill would be ac-
cepted by the public, developers should take into account
the public preference for a high quality and low burden
screening test. Estimates from user preferences during the
development of diagnostic technologies could be used to
identify relative performance, including perceived benefits
and harms compared to competitors, allowing for changes
to be made throughout the process of development.Additional files
Additional file 1: This file contains the descriptions of the different
screening tests as displayed to the respondents.
Additional file 2: This file contains a sample of the questionnaire
that was sent to the respondents. Since we used a randomised design
in Sawtooth for the conjoint questions, each respondent got different
but the same number of choicesets to compare.
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